메뉴 건너뛰기




Volumn 6, Issue 4, 2009, Pages 231-240

Current treatment of psoriasis with biologics

Author keywords

Antibodies; Autoimmunity; Chronic inflammation; Clinical trials; Th17 cells

Indexed keywords

ADALIMUMAB; AIN 457; ALEFACEPT; ANTIPSORIASIS AGENT; BETA DEFENSIN 2; CD68 ANTIGEN; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PSORALEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

EID: 70449718874     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309789869092     Document Type: Review
Times cited : (15)

References (78)
  • 2
    • 14244267601 scopus 로고    scopus 로고
    • Psoriasis: Epidemiology, clinical features, and quality of life
    • Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl 2): ii18-23.
    • (2005) Ann Rheum Dis , vol.64 , Issue.SUPPL. 2
    • Langley, R.G.1    Krueger, G.G.2    Griffiths, C.E.3
  • 3
    • 20444497652 scopus 로고    scopus 로고
    • Psoriasis - Recent advances in understanding its pathogenesis and treatment
    • DOI 10.1016/j.jaad.2005.04.035, PII S0190962205013137, New Strategies for Optimizing the Treatment of Inflamatory Dermatoses with Topical Corticosteroids in an Era of Costisosteroids-Sparing
    • Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53(1 Suppl 1): S94-100. (Pubitemid 40828186)
    • (2005) Journal of the American Academy of Dermatology , vol.53 , Issue.1 SUPPL.
    • Krueger, G.1    Ellis, C.N.2
  • 4
    • 65349134699 scopus 로고    scopus 로고
    • Psoriasis bench to bedside: Genetics meets immunology
    • Nair RP, Ding J, Duffin KC, et al. Psoriasis bench to bedside: Genetics meets immunology. Arch Dermatol 2009; 145(4): 462-464
    • (2009) Arch Dermatol , vol.145 , Issue.4 , pp. 462-464
    • Nair, R.P.1    Ding, J.2    Duffin, K.C.3
  • 5
    • 14244258610 scopus 로고    scopus 로고
    • Psoriasis pathophysiology: Current concepts of pathogenesis
    • DOI 10.1136/ard.2004.031120
    • Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 2005; 64(Suppl 2): ii30-6. (Pubitemid 40288517)
    • (2005) Annals of the Rheumatic Diseases , vol.64 , Issue.SUPPL. 2
    • Krueger, J.G.1    Bowcock, A.2
  • 7
    • 48849107322 scopus 로고    scopus 로고
    • Psoriasis, metabolic syndrome and its components
    • Ortonne JP. Psoriasis, metabolic syndrome and its components. Ann Dermatol Vénéréol 2008; 135(Suppl 4): 235-242
    • (2008) Ann Dermatol Vénéréol , vol.135 , Issue.SUPPL. 4 , pp. 235-242
    • Ortonne, J.P.1
  • 8
    • 58049198305 scopus 로고    scopus 로고
    • Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome
    • Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144(12): 1571-1575
    • (2008) Arch Dermatol , vol.144 , Issue.12 , pp. 1571-1575
    • Chen, Y.J.1    Wu, C.Y.2    Shen, J.L.3
  • 9
    • 54249136408 scopus 로고    scopus 로고
    • Comedication related to comorbidities: A study in 1203 hospitalized patients with severe psoriasis
    • Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: A study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008; 159(5): 1116-1123
    • (2008) Br J Dermatol , vol.159 , Issue.5 , pp. 1116-1123
    • Gerdes, S.1    Zahl, V.A.2    Knopf, H.3
  • 10
    • 0033044964 scopus 로고    scopus 로고
    • The pathogenesis of psoriasis: Immunological facts and speculations
    • Bos JD, de Rie MA. The pathogenesis of psoriasis: Immunological facts and speculations. Immunol Today 1999; 20(1): 40-46
    • (1999) Immunol Today , vol.20 , Issue.1 , pp. 40-46
    • Bos, J.D.1    De Rie, M.A.2
  • 11
    • 25844505509 scopus 로고    scopus 로고
    • The genetics of psoriasis and autoimmunity
    • Bowcock AM. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet 2005; 6: 93-122.
    • (2005) Annu Rev Genomics Hum Genet , vol.6 , pp. 93-122
    • Bowcock, A.M.1
  • 12
    • 33750282677 scopus 로고    scopus 로고
    • The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation
    • Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006; 18(6): 670-675
    • (2006) Curr Opin Immunol , vol.18 , Issue.6 , pp. 670-675
    • Kikly, K.1    Liu, L.2    Na, S.3    Sedgwick, J.D.4
  • 14
    • 36049052516 scopus 로고    scopus 로고
    • Interleukin-12, interleukin-23, and psoriasis: Current prospects
    • Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: Current prospects. J Am Acad Dermatol 2007; 57(6): 1059-1068
    • (2007) J Am Acad Dermatol , vol.57 , Issue.6 , pp. 1059-1068
    • Torti, D.C.1    Feldman, S.R.2
  • 15
    • 31144441631 scopus 로고    scopus 로고
    • In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin
    • Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 2006; 176(3): 1908-1915
    • (2006) J Immunol , vol.176 , Issue.3 , pp. 1908-1915
    • Piskin, G.1    Sylva-Steenland, R.M.2    Bos, J.D.3    Teunissen, M.B.4
  • 16
    • 33846906224 scopus 로고    scopus 로고
    • H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
    • DOI 10.1038/nature05505, PII NATURE05505
    • Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445(7128): 648-651 (Pubitemid 46232884)
    • (2007) Nature , vol.445 , Issue.7128 , pp. 648-651
    • Zheng, Y.1    Danilenko, D.M.2    Valdez, P.3    Kasman, I.4    Eastham-Anderson, J.5    Wu, J.6    Ouyang, W.7
  • 17
    • 0037449737 scopus 로고    scopus 로고
    • Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
    • DOI 10.1074/jbc.M207577200
    • Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 + T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278(3): 1910-1914 (Pubitemid 36801431)
    • (2003) Journal of Biological Chemistry , vol.278 , Issue.3 , pp. 1910-1914
    • Aggarwal, S.1    Ghilardi, N.2    Xie, M.-H.3    De Sauvage, F.J.4    Gurney, A.L.5
  • 18
    • 0033638507 scopus 로고    scopus 로고
    • Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
    • Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13(5): 715-725
    • (2000) Immunity , vol.13 , Issue.5 , pp. 715-725
    • Oppmann, B.1    Lesley, R.2    Blom, B.3
  • 19
    • 33847757147 scopus 로고    scopus 로고
    • Cracking the cytokine code in psoriasis
    • Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13(3): 242-244
    • (2007) Nat Med , vol.13 , Issue.3 , pp. 242-244
    • Nickoloff, B.J.1
  • 21
    • 33845337658 scopus 로고    scopus 로고
    • Genomics and proteomics: Emerging technologies in clinical cancer research
    • DOI 10.1016/j.critrevonc.2006.06.005, PII S1040842806001090
    • Chung CH, Levy S, Chaurand P, Carbone DP. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol 2006; 61(1): 1-25. (Pubitemid 44880146)
    • (2007) Critical Reviews in Oncology/Hematology , vol.61 , Issue.1 , pp. 1-25
    • Chung, C.H.1    Levy, S.2    Chaurand, P.3    Carbone, D.P.4
  • 23
    • 31444431754 scopus 로고    scopus 로고
    • Reliability and reproducibility issues in DNA microarray measurements
    • DOI 10.1016/j.tig.2005.12.005, PII S0168952505003598
    • Draghici S, Khatri P, Eklund AC, et al. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006; 22(2): 101-109 (Pubitemid 43152029)
    • (2006) Trends in Genetics , vol.22 , Issue.2 , pp. 101-109
    • Draghici, S.1    Khatri, P.2    Eklund, A.C.3    Szallasi, Z.4
  • 25
    • 0035756813 scopus 로고    scopus 로고
    • Molecular classification of psoriasis diseaseassociated genes through pharmacogenomic expression profiling
    • Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1(4): 272-287 (Pubitemid 33756652)
    • (2001) Pharmacogenomics Journal , vol.1 , Issue.4 , pp. 272-287
    • Oestreicher, J.L.1    Walters, I.B.2    Kikuchi, T.3    Gilleaudeau, P.4
  • 27
    • 0037453146 scopus 로고    scopus 로고
    • Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array
    • Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13(1): 69-78. (Pubitemid 37129170)
    • (2003) Physiological Genomics , vol.13 , pp. 69-78
    • Zhou, X.1    Krueger, J.G.2    Kao, M.-C.J.3    Lee, E.4    Du, F.5    Menter, A.6    Wong, W.H.7    Bowcock, A.M.8
  • 29
    • 4644309388 scopus 로고    scopus 로고
    • Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment
    • Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51(4): 563-569
    • (2004) J Am Acad Dermatol , vol.51 , Issue.4 , pp. 563-569
    • Langley, R.G.1    Ellis, C.N.2
  • 30
    • 62049084468 scopus 로고    scopus 로고
    • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
    • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60(4): 643-659
    • (2009) J Am Acad Dermatol , vol.60 , Issue.4 , pp. 643-659
    • Menter, A.1    Korman, N.J.2    Elmets, C.A.3
  • 31
    • 68949149916 scopus 로고    scopus 로고
    • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61(3): 451-485
    • (2009) J Am Acad Dermatol , vol.61 , Issue.3 , pp. 451-485
    • Menter, A.1    Korman, N.J.2    Elmets, C.A.3
  • 32
    • 0036344554 scopus 로고    scopus 로고
    • Clinical features of psoriatic arthritis
    • Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care 2002; 8(6 Suppl): S160-70.
    • (2002) Am J Manag Care , vol.8 , Issue.6 SUPPL.
    • Krueger, G.G.1
  • 33
    • 65349091931 scopus 로고    scopus 로고
    • Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial
    • Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145(4): 387-393
    • (2009) Arch Dermatol , vol.145 , Issue.4 , pp. 387-393
    • Mittal, R.1    Malhotra, S.2    Pandhi, P.3    Kaur, I.4    Dogra, S.5
  • 34
    • 56549084244 scopus 로고    scopus 로고
    • Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis
    • Lin YK, Chang CJ, Chang YC, Wong WR, Chang SC, Pang JH. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol 2008; 144(11): 1457-1464
    • (2008) Arch Dermatol , vol.144 , Issue.11 , pp. 1457-1464
    • Lin, Y.K.1    Chang, C.J.2    Chang, Y.C.3    Wong, W.R.4    Chang, S.C.5    Pang, J.H.6
  • 35
    • 0024314554 scopus 로고
    • Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
    • Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2(8657): 244-247 (Pubitemid 19180612)
    • (1989) Lancet , vol.2 , Issue.8657 , pp. 244-247
    • Brennan, F.M.1    Jackson, A.2    Chantry, D.3    Maini, R.4    Feldmann, M.5
  • 36
    • 0036584028 scopus 로고    scopus 로고
    • Development of anti-TNF therapy for rheumatoid arthritis
    • Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2(5): 364-371 (Pubitemid 37328759)
    • (2002) Nature Reviews Immunology , vol.2 , Issue.5 , pp. 364-371
    • Feldmann, M.1
  • 37
    • 47249153519 scopus 로고    scopus 로고
    • Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics
    • DOI 10.1111/j.1600-065X.2008.00626.x
    • Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7-19. (Pubitemid 351986171)
    • (2008) Immunological Reviews , vol.223 , Issue.1 , pp. 7-19
    • Feldmann, M.1    Maini, S.R.N.2
  • 38
    • 41949094481 scopus 로고    scopus 로고
    • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Over-view of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    • Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Over-view of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5): 826-850
    • (2008) J Am Acad Dermatol , vol.58 , Issue.5 , pp. 826-850
    • Menter, A.1    Gottlieb, A.2    Feldman, S.R.3
  • 39
    • 41949096736 scopus 로고    scopus 로고
    • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics
    • Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58(5): 851-864
    • (2008) J Am Acad Dermatol , vol.58 , Issue.5 , pp. 851-864
    • Gottlieb, A.1    Korman, N.J.2    Gordon, K.B.3
  • 40
    • 0035954670 scopus 로고    scopus 로고
    • Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
    • Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345(4): 248-255
    • (2001) N Engl J Med , vol.345 , Issue.4 , pp. 248-255
    • Ellis, C.N.1    Krueger, G.G.2
  • 41
    • 0348134794 scopus 로고    scopus 로고
    • Treatment of Psoriasis with Alefacept: Correlation of Clinical Improvement with Reductions of Memory T-Cell Counts
    • DOI 10.1001/archderm.139.12.1563
    • Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139(12): 1563-1570 (Pubitemid 37523074)
    • (2003) Archives of Dermatology , vol.139 , Issue.12 , pp. 1563-1570
    • Gordon, K.B.1    Vaishnaw, A.K.2    O'Gorman, J.3    Haney, J.4    Menter, A.5
  • 42
    • 0036895587 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
    • Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47(6): 821-833
    • (2002) J Am Acad Dermatol , vol.47 , Issue.6 , pp. 821-833
    • Krueger, G.G.1    Papp, K.A.2    Stough, D.B.3    Loven, K.H.4    Gulliver, W.P.5    Ellis, C.N.6
  • 43
    • 0038385972 scopus 로고    scopus 로고
    • An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
    • DOI 10.1001/archderm.139.6.719
    • Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebocontrolled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139(6): 719-727 (Pubitemid 36705938)
    • (2003) Archives of Dermatology , vol.139 , Issue.6 , pp. 719-727
    • Lebwohl, M.1    Christophers, E.2    Langley, R.3    Ortonne, J.P.4    Roberts, J.5    Griffiths, C.E.M.6
  • 44
    • 29244464655 scopus 로고    scopus 로고
    • The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    • DOI 10.1016/j.jaad.2005.10.006, PII S0190962205032330
    • Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006; 54(1): 61-63 (Pubitemid 41832458)
    • (2006) Journal of the American Academy of Dermatology , vol.54 , Issue.1 , pp. 61-63
    • Menter, A.1    Cather, J.C.2    Baker, D.3    Farber, H.F.4    Lebwohl, M.5    Darif, M.6
  • 46
    • 17144388751 scopus 로고    scopus 로고
    • Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
    • Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52(3 Pt 1): 425-433
    • (2005) J Am Acad Dermatol , vol.52 , Issue.3 PART 1 , pp. 425-433
    • Leonardi, C.L.1    Papp, K.A.2    Gordon, K.B.3
  • 47
    • 42049083573 scopus 로고    scopus 로고
    • Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis
    • Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008; 158(5): 1107-1116
    • (2008) Br J Dermatol , vol.158 , Issue.5 , pp. 1107-1116
    • Leonardi, C.1    Menter, A.2    Hamilton, T.3    Caro, I.4    Xing, B.5    Gottlieb, A.B.6
  • 49
    • 0034729950 scopus 로고    scopus 로고
    • Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
    • Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356(9227): 385-390 (Pubitemid 30487495)
    • (2000) Lancet , vol.356 , Issue.9227 , pp. 385-390
    • Mease, P.J.1    Goffe, B.S.2    Metz, J.3    Vanderstoep, A.4    Finck, B.5    Burge, D.J.6
  • 52
    • 32644437923 scopus 로고    scopus 로고
    • Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database
    • Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54(3 Suppl 2): S92-100.
    • (2006) J Am Acad Dermatol , vol.54 , Issue.3 SUPPL. 2
    • Gottlieb, A.B.1    Leonardi, C.L.2    Goffe, B.S.3
  • 56
    • 26644433889 scopus 로고    scopus 로고
    • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial
    • DOI 10.1016/S0140-6736(05)67566-6, PII S0140673605675666
    • Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005; 366(9494): 1367-1374 (Pubitemid 41443403)
    • (2005) Lancet , vol.366 , Issue.9494 , pp. 1367-1374
    • Reich, K.1    Nestle, F.O.2    Papp, K.3    Ortonne, J.-P.4    Evans, R.5    Guzzo, C.6    Li, S.7    Dooley, L.T.8    Griffiths, C.E.M.9
  • 60
    • 0037292855 scopus 로고    scopus 로고
    • Infection complications associated with the use of biologic agents
    • DOI 10.1016/S0889-857X(02)00101-1, PII S0889857X02001011
    • Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29(1): 185-202. (Pubitemid 36298110)
    • (2003) Rheumatic Disease Clinics of North America , vol.29 , Issue.1 , pp. 185-202
    • Bresnihan, B.1    Cunnane, G.2
  • 61
    • 57649220625 scopus 로고    scopus 로고
    • Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: A report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians
    • Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: A report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160(1): 8-15.
    • (2009) Br J Dermatol , vol.160 , Issue.1 , pp. 8-15
    • Perlmutter, A.1    Mittal, A.2    Menter, A.3
  • 62
    • 0037532694 scopus 로고    scopus 로고
    • Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [6]
    • DOI 10.1136/ard.62.7.686
    • Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62(7): 686-687 (Pubitemid 36760576)
    • (2003) Annals of the Rheumatic Diseases , vol.62 , Issue.7 , pp. 686-687
    • Ostuni, P.1    Botsios, C.2    Punzi, L.3    Sfriso, P.4    Todesco, S.5
  • 63
    • 0037116836 scopus 로고    scopus 로고
    • Drug-induced systemic lupus erythematosus associated with etanercept therapy
    • DOI 10.1016/S0140-6736(02)07714-0
    • Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359(9306): 579-580 (Pubitemid 34178442)
    • (2002) Lancet , vol.359 , Issue.9306 , pp. 579-580
    • Shakoor, N.1    Michalska, M.2    Harris, C.A.3    Block, J.A.4
  • 65
    • 43449094043 scopus 로고    scopus 로고
    • Ustekinumab for chronic plaque psoriasis
    • Bartlett BL, Tyring S.K. Ustekinumab for chronic plaque psoriasis. Lancet 2008; 371(9625): 1639-1640
    • (2008) Lancet , vol.371 , Issue.9625 , pp. 1639-1640
    • Bartlett, B.L.1    Tyring, S.K.2
  • 66
    • 43449111187 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    • DOI 10.1016/S0140-6736(08)60725-4, PII S0140673608607254
    • Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371(9625): 1665-1674 (Pubitemid 351671883)
    • (2008) The Lancet , vol.371 , Issue.9625 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3    Yeilding, N.4    Guzzo, C.5    Wang, Y.6    Li, S.7    Dooley, L.T.8    Gordon, K.B.9
  • 67
    • 43449139402 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    • DOI 10.1016/S0140-6736(08)60726-6, PII S0140673608607266
    • Papp KA, Langley RG, Lebwohl M, et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371(9625): 1675-1684 (Pubitemid 351671884)
    • (2008) The Lancet , vol.371 , Issue.9625 , pp. 1675-1684
    • Papp, K.A.1    Langley, R.G.2    Lebwohl, M.3    Krueger, G.G.4    Szapary, P.5    Yeilding, N.6    Guzzo, C.7    Hsu, M.-C.8    Wang, Y.9    Li, S.10    Dooley, L.T.11    Reich, K.12
  • 68
    • 70449712998 scopus 로고    scopus 로고
    • Ustekinumab in the therapy of chronic plaque psoriasis
    • O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 2009; 3: 159-168
    • (2009) Biologics , vol.3 , pp. 159-168
    • O'Neill, J.L.1    Kalb, R.E.2
  • 69
    • 33750390154 scopus 로고    scopus 로고
    • Immune therapies of autoimmune diseases: Are we approaching a real cure?
    • Chatenoud L. Immune therapies of autoimmune diseases: are we approaching a real cure? Curr Opin Immunol 2006; 18(6): 710-717
    • (2006) Curr Opin Immunol , vol.18 , Issue.6 , pp. 710-717
    • Chatenoud, L.1
  • 70
    • 41649084155 scopus 로고    scopus 로고
    • At the horizon of innovative therapy in rheumatology: New biologic agents
    • Finckh A, Gabay C. At the horizon of innovative therapy in rheumatology: New biologic agents. Curr Opin Rheumatol 2008; 20(3): 269-275
    • (2008) Curr Opin Rheumatol , vol.20 , Issue.3 , pp. 269-275
    • Finckh, A.1    Gabay, C.2
  • 71
    • 41549158609 scopus 로고    scopus 로고
    • Cytokines as therapeutic targets: Advances and limitations
    • Scheinecker C, Redlich K, Smolen JS. Cytokines as therapeutic targets: Advances and limitations. Immunity 2008; 28(4): 440-444
    • (2008) Immunity , vol.28 , Issue.4 , pp. 440-444
    • Scheinecker, C.1    Redlich, K.2    Smolen, J.S.3
  • 72
    • 0028143211 scopus 로고
    • Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
    • Elliott MJ, R.N. Maini, M. Feldmann, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344(8930): 1105-1110
    • (1994) Lancet , vol.344 , Issue.8930 , pp. 1105-1110
    • Elliott, M.J.1    Maini, R.N.2    Feldmann, M.3
  • 73
    • 18644385243 scopus 로고    scopus 로고
    • Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
    • DOI 10.1084/jem.20050473
    • Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201(9): 1479-1486 (Pubitemid 40664091)
    • (2005) Journal of Experimental Medicine , vol.201 , Issue.9 , pp. 1479-1486
    • Pascual, V.1    Allantaz, F.2    Arce, E.3    Punaro, M.4    Banchereau, J.5
  • 75
    • 34447300492 scopus 로고    scopus 로고
    • Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
    • DOI 10.1136/ard.2006.068064
    • Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66(9): 1162-1167 (Pubitemid 47309731)
    • (2007) Annals of the Rheumatic Diseases , vol.66 , Issue.9 , pp. 1162-1167
    • Nishimoto, N.1    Hashimoto, J.2    Miyasaka, N.3    Yamamoto, K.4    Kawai, S.5    Takeuchi, T.6    Murata, N.7    Van Heijde, D.D.8    Kishimoto, T.9
  • 76
    • 54949150604 scopus 로고    scopus 로고
    • Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
    • Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58(10): 2968-2980
    • (2008) Arthritis Rheum , vol.58 , Issue.10 , pp. 2968-2980
    • Genovese, M.C.1    McKay, J.D.2    Nasonov, E.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.